Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis:: Results of a double-blind, placebo-controlled 3-year study
Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis:: Results of a double-blind, placebo-controlled 3-year study
复制标题
DOI：
10.1359/jbmr.040116
复制
发表时间：
2004-05-01
影响因子：
6.2
通讯作者：
Kanis, JA
中科院分区：
文献类型：
--
作者：
McCloskey, E;Selby, P;Kanis, JA
对593名绝经后或继发性骨质疏松症患者每日口服800 mg氯屈膦酸盐减少椎体骨折的疗效进行了研究。椎体骨折发生率明显下降46%。骨质疏松症的潜在原因或包括骨密度、QUS、体重和吸烟在内的其他基线因素不会影响该效应。
The efficacy of oral clodronate 800 mg daily to reduce vertebral fractures was studied in 593 women with postmenopausal or secondary osteoporosis. The incidence of vertebral fractures was significantly reduced by 46%. The effect was not modified by the underlying cause of osteoporosis or other baseline factors including bone mineral density, QUS, weight, and smoking.